InxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
/PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis,...
United States James Mcleod Prnewswire Inxmed Co Ltd China National Medical Products Administration University Chinese Academy Of Sciences Drug Administration
Source: prnewswire.com